Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

We herein report a case of the beneficial effect of osimertinib readministration in non-small-cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A 69-year-old non-smoking woman was diagnosed with advanced NSCLC harboring an EGFR exon19 deletion and T790M. She was...

Descripción completa

Detalles Bibliográficos
Autores principales: Makimoto, Go, Ohashi, Kadoaki, Senoo, Satoru, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599916/
https://www.ncbi.nlm.nih.gov/pubmed/30713295
http://dx.doi.org/10.2169/internalmedicine.2152-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599916/
https://www.ncbi.nlm.nih.gov/pubmed/30713295
http://dx.doi.org/10.2169/internalmedicine.2152-18

Ejemplares similares